{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:10:51Z","timestamp":1794330651517,"version":"4.9.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>IgD multiple myeloma (MM) is a rare subtype of MM and light chain deposition disease (LCDD) outside the kidney is also a rare and has scarcely been reported. We report herein the details of the first reported case of LCDD involving the kidney and liver co-occurring with IgD myeloma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 66-year-old female with IgD MM presented with rapidly progressive acute renal failure, ascites and pleural effusion. Immunofluorescent study of revealed the characteristic linear deposition of Ig<jats:italic>\u03ba<\/jats:italic>light chain along the glomerular and tubular basement membrane in kidney. Electron microscopy showed the powdery electron-dense deposits along the tubular and glomerular basement membrane consistent with the diagnosis of LCDD. Laser microdissection followed by mass spectrometry identified only Ig\u03ba light chain with more than 95% probability confirm the diagnosis of \u03ba-LCDD but not heavy\/light chain deposition disease. Liver biopsy with immunofluorescence study revealed the linear deposition of Ig\u03ba chain along the perisinusoidal space indicating the hepatic involvement of \u03ba-LCDD. The patient was successfully treated with combination therapy with bortezomib, cyclophosphamide, dexamethasone, and daratumumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This report emphasizes that prompt biopsy of affected organs and initiation of clone directed therapy led to the correct diagnosis and favorable outcome in patient with LCDD who has extrarenal involvement.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-021-02246-9","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T08:02:59Z","timestamp":1611388979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Light chain deposition disease involving kidney and liver in a patient with IgD myeloma"],"prefix":"10.1186","volume":"22","author":[{"given":"Takafumi","family":"Tsushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimuzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"issue":"7","key":"2246_CR1","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V1271482","volume":"12","author":"J Lin","year":"2001","unstructured":"Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12(7):1482\u201392.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2246_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1681\/ASN.2017121319","volume":"29","author":"S Sethi","year":"2018","unstructured":"Sethi S, Rajkumar SV, D'Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol. 2018;29(7):1810\u201323.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2246_CR3","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1053\/j.ajkd.2003.08.040","volume":"42","author":"C Pozzi","year":"2003","unstructured":"Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42(6):1154\u201363.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2246_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2215\/CJN.08640811","volume":"7","author":"SH Nasr","year":"2012","unstructured":"Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"26","key":"2246_CR5","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","volume":"126","author":"RH Sayed","year":"2015","unstructured":"Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, et al. Natural history and outcome of light chain deposition disease. Blood. 2015;126(26):2805\u201310.","journal-title":"Blood."},{"issue":"9","key":"2246_CR6","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","volume":"32","author":"M Gavriatopoulou","year":"2018","unstructured":"Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883\u201398.","journal-title":"Leukemia."},{"issue":"11","key":"2246_CR7","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","volume":"12","author":"J Blade","year":"1994","unstructured":"Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398\u2013404.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2246_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/annonc\/mdq393","volume":"22","author":"MK Kim","year":"2011","unstructured":"Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22(2):411\u20136.","journal-title":"Ann Oncol"},{"issue":"4","key":"2246_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1681\/ASN.2014050481","volume":"26","author":"V Royal","year":"2015","unstructured":"Royal V, Quint P, Leblanc M, LeBlanc R, Duncanson GF, Perrizo RL, et al. IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol. 2015;26(4):784\u201390.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2246_CR10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","volume":"133","author":"F Joly","year":"2019","unstructured":"Joly F, Cohen C, Javaugue V, Bender S, Belmouaz M, Arnulf B, et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 2019;133(6):576\u201387.","journal-title":"Blood."},{"issue":"8","key":"2246_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ajh.24756","volume":"92","author":"M Mohan","year":"2017","unstructured":"Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017;92(8):739\u201345.","journal-title":"Am J Hematol"},{"issue":"1","key":"2246_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1600-0609.2005.00561.x","volume":"76","author":"C Samanez","year":"2006","unstructured":"Samanez C, Domingo A, Cibeira MT, Miquel R, Soler M, Blade J. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. Eur J Haematol. 2006;76(1):83\u20135.","journal-title":"Eur J Haematol"},{"issue":"3","key":"2246_CR13","first-page":"000545","volume":"4","author":"A Cristino","year":"2017","unstructured":"Cristino A, Pais C, Silva R, Carrola P. Light-chain deposition disease with prominent hepatic involvement. Eur J Case Rep Intern Med. 2017;4(3):000545.","journal-title":"Eur J Case Rep Intern Med"},{"issue":"5","key":"2246_CR14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ki.2015.201","volume":"88","author":"C Cohen","year":"2015","unstructured":"Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 2015;88(5):1135\u201343.","journal-title":"Kidney Int"},{"issue":"6","key":"2246_CR15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/ndt\/gfq023","volume":"25","author":"I Petrakis","year":"2010","unstructured":"Petrakis I, Stylianou K, Mavroeidi V, Vardaki E, Stratigis S, Stratakis S, et al. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrol Dial Transplant. 2010;25(6):2020\u20133.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2246_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612\u20135.","journal-title":"Blood."},{"issue":"18","key":"2246_CR17","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood.2019004369","volume":"135","author":"M Roussel","year":"2020","unstructured":"Roussel M, Merlini G, Chevret S, Arnulf B, Stoppa AM, Perrot A, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531\u201340.","journal-title":"Blood."},{"issue":"7","key":"2246_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/bloodadvances.2020001553","volume":"4","author":"P Milani","year":"2020","unstructured":"Milani P, Basset M, Curci P, Foli A, Rizzi R, Nuvolone M, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Adv. 2020;4(7):1321\u20134.","journal-title":"Blood Adv"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-021-02246-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:35:17Z","timestamp":1670891717000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02246-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2246"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02246-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"12 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient described in this report was fully informed on her examination and treatment approved by Institutional Review Broad of the Kameda Medical Center in accordance with Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that all authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}